← Back to the fund page Use your browser's print dialog and choose “Save as PDF”. A4.
MF Analyser

Tata India Pharma & Healthcare Fund

Regular Plan · Growth Option · Sectoral / Thematic · Scheme code 135812

NAV₹33.1867as on 25 Sep 2026
Fund houseTata Mutual Fund
CategorySectoral / Thematic
Plan & optionRegular · Growth Option
History10.7 years

Returns (%)

 1M3M6M1Y3Y5Y7Y10YLaunch
This scheme -2.134.5512.98 6.0817.0812.41 20.3012.9011.69
Nifty 500
benchmark		 0.874.312.15 5.2012.4911.41 ——15.49
Sectoral / Thematic
category median		 ——— 2.2113.4710.56 —13.46—

Over a year annualised (CAGR), under a year absolute. Computed from AMFI's published NAV history for this scheme.

Risk

 VolatilitySharpeSortinoBetaAlphaMax fallR²
This scheme 15.1% 0.70 1.02 0.62 9.68% -21.9% 43.60
Nifty 500
benchmark		 17.2%0.35 0.47—— -37.3%—

Risk-free rate 6.5%. Beta, alpha and R² are regressed on the 83 months this scheme and its benchmark share.

Growth of ₹100 since launch

58158259360201620182020202220242026MF Analyser

Drawdown from peak (%)

0%-8%-16%-25%201620182020202220242026

Every one-year period it has lived through

WindowsWorstMedianBestPeriods that lost money
479 -18.1% 7.0% 73.7% 34%

Every one-year holding period in this scheme's history, not just the last one — the spread a real investor would have met depending only on when they started.

How it behaves against its benchmark

Up captureDown captureCorrelation Tracking errorInformation ratioTreynor
90% 45% 0.66 14.5% 0.45 24.02

Up capture is how much of the benchmark's gain this scheme kept in the months the benchmark rose; down capture, how much of its fall it took. Below 100 on the down side and above it on the up side is the combination every fund is trying for and few reach. Measured over the 83 months this scheme and Nifty 500 share.

MF Analyser

Tata India Pharma & Healthcare Fund

Regular Plan · Growth Option

Allocation

By asset

Equity99.49%
Cash & Equivalents0.51%

By market cap

Large Cap23.29%
Mid Cap36.13%
Small Cap37.32%
Unclassified2.75%

Concentration

Number of stocks41
Top 5 stocks30.29%
Top 10 stocks50.19%
Top 20 stocks77.44%
Lines in the filing44
Largest holding8.43%
Largest sectorPharmaceuticals & Biotechnology 58.28%
Effective stocks26.6
Sectors held5
Cash0.51%

Effective stocks is what the concentration works out to: a fund holding 41 names but most of its money in a few behaves like a fund of 27. Cash includes repo and TREPS, which every fund parks money in overnight.

Sector split

Pharmaceuticals & Biotechnology — 58.3%Healthcare Services — 34.1%Fertilizers & Agrochemicals — 5.6%Other — 2.1%Pharmaceuticals & Biotech…58.3%Healthcare Services34.1%Fertilizers & Agrochemica…5.6%Other2.1%
Pharmaceuticals & Biotechnology58.28%
Healthcare Services34.07%
Fertilizers & Agrochemicals5.55%
Personal Products1.09%
Cash & Equivalents0.51%
Insurance0.50%
MF Analyser

Tata India Pharma & Healthcare Fund

Regular Plan · Growth Option · holdings

Top 30 holdings

#CompanySectorShares held Value
₹ cr		% of fund
1 SUN PHARMACEUTICAL INDUSTRIES LTD Pharmaceuticals & Biotechnology 665,178 132 8.43%
2 HEALTHCARE GLOBAL ENTERPRISES LTD Healthcare Services 1,344,012 99 6.30%
3 DIVI LABORATORIES LTD Pharmaceuticals & Biotechnology 93,472 88 5.65%
4 ABBOTT INDIA LTD Pharmaceuticals & Biotechnology 32,924 85 5.44%
5 RAINBOW CHILDRENS MEDICARE LTD Healthcare Services 495,081 70 4.47%
6 APOLLO HOSPITALS ENTERPRISE LTD Healthcare Services 76,013 68 4.32%
7 CIPLA LTD Pharmaceuticals & Biotechnology 473,861 67 4.27%
8 DR REDDYS LABORATORIES LTD Pharmaceuticals & Biotechnology 570,312 66 4.21%
9 MAX HEALTHCARE INSTITUTE LTD Healthcare Services 571,483 60 3.80%
10 FORTIS HEALTHCARE LTD Healthcare Services 569,351 52 3.30%
11 LUPIN LTD Pharmaceuticals & Biotechnology 233,454 51 3.26%
12 SYNGENE INTERNATIONAL LTD Healthcare Services 1,179,871 47 3.02%
13 BAYER CROPSCIENCE LTD Fertilizers & Agrochemicals 118,817 47 3.01%
14 PFIZER LTD Pharmaceuticals & Biotechnology 97,680 46 2.92%
15 MANKIND PHARMA LTD Pharmaceuticals & Biotechnology 188,404 46 2.91%
16 GLAXOSMITHKLINE PHARMACEUTICALS LTD Pharmaceuticals & Biotechnology 139,758 43 2.72%
17 PROCTER & GAMBLE HEALTH LTD Pharmaceuticals & Biotechnology 67,994 39 2.51%
18 SAI LIFE SCIENCES LTD Pharmaceuticals & Biotechnology 258,078 38 2.41%
19 ALKEM LABORATORIES LTD Pharmaceuticals & Biotechnology 69,058 37 2.35%
20 ANTHEM BIOSCIENCES LTD Pharmaceuticals & Biotechnology 374,406 33 2.14%
21 FDC LTD Pharmaceuticals & Biotechnology 975,769 33 2.10%
22 GLOBAL HEALTH LTD Healthcare Services 177,820 26 1.68%
23 DR. LAL PATH LABS LTD Healthcare Services 134,222 26 1.66%
24 ASTER DM QUALITY CARE LTD Healthcare Services 329,708 25 1.59%
25 SUMITOMO CHEMICAL INDIA LTD Fertilizers & Agrochemicals 479,951 25 1.59%
26 AJANTA PHARMA LTD Pharmaceuticals & Biotechnology 68,052 25 1.57%
27 ACUTAAS CHEMICALS LTD Pharmaceuticals & Biotechnology 73,399 23 1.48%
28 MANIPAL HEALTH ENTERPRISES LTD Healthcare Services 253,500 19 1.24%
29 METROPOLIS HEALTHCARE LTD Healthcare Services 297,347 17 1.11%
30 GILLETTE INDIA LTD Personal Products 23,237 17 1.09%
MF Analyser

Tata India Pharma & Healthcare Fund

Regular Plan · Growth Option · where the money sits

What the manager did last month

Between the filings of 31 Jul 2026 and 31 Aug 2026. A position grows because the manager bought or because the price rose; only the share count separates them.

BoughtSoldNew positionsSold out ofPrice move of holdings
₹83 cr ₹103 cr 8 4 +0.37%
StockShares tradedShares PriceValue
₹ cr
New position
ASTER DM QUALITY CARE LTD 329,708 entered — 24.9
ACUTAAS CHEMICALS LTD 73,399 entered — 23.2
PI INDUSTRIES LTD 63,066 entered — 15.0
IPCA LABORATORIES LTD 71,536 entered — 14.1
MOLBIO DIAGNOSTICS LTD 125,804 entered — 13.7
SYMBIOTEC PHARMALAB LTD 101,220 entered — 10.0
HDFC LIFE INSURANCE CO. LTD 145,063 entered — 7.9
TORRENT PHARMACEUTICALS LTD 3,740 entered — 1.9
Added to
ANTHEM BIOSCIENCES LTD 373,006 +26,643.3% +10.4% 33.3
LUPIN LTD 64,676 +38.3% -9.4% 14.2
APOLLO HOSPITALS ENTERPRISE LTD 8,820 +13.1% -0.7% 7.9
BIOCON LTD 188,838 +100.7% -3.2% 7.8
PROCTER & GAMBLE HEALTH LTD 11,597 +20.6% -12.7% 6.7
FORTIS HEALTHCARE LTD 60,000 +11.8% -4.0% 5.4
ABBOTT INDIA LTD 1,693 +5.4% -7.0% 4.4
FDC LTD 76,851 +8.6% -17.7% 2.6
Trimmed
GLAXOSMITHKLINE PHARMACEUTICALS LTD 130,905 -48.4% +14.9% 39.9
DIVI LABORATORIES LTD 28,173 -23.2% +17.5% 26.7
SAI LIFE SCIENCES LTD 80,414 -23.8% +11.0% 11.7
GLOBAL HEALTH LTD 56,126 -24.0% +5.3% 8.3
DR. LAL PATH LABS LTD 41,638 -23.7% +1.5% 8.1
JUBILANT PHARMOVA LTD 91,087 -66.9% -5.7% 8.0
GILLETTE INDIA LTD 53 -0.2% -3.9% 0.0
Sold out of
CONCORD BIOTECH LTD 207,380 exited — 29.5
NEULAND LABORATORIES LTD 10,134 exited — 19.3
BASF INDIA LTD 41,008 exited — 14.9
SANOFI INDIA LTD 10,635 exited — 3.5
Not equityPrevious filingThis filingChange
Cash, repo and TREPS ₹0 cr ₹0 cr +₹0 cr

The list above is stocks and fund units. Treasury bills, repo and money-market lines roll over every month by design — they are not decisions, so they are totalled here rather than listed as activity.

A ₹10,000 monthly SIP over five years

InvestedValueGainXIRR
₹600,000 ₹891,688 ₹291,688 15.85%

XIRR, not CAGR — a SIP's money arrives over sixty months, so each instalment has been invested for a different length of time.

Not investment advice. InvestVerdict is not a SEBI-registered Investment Adviser or Research Analyst. Every figure is computed from AMFI's published NAV history and the portfolio the AMC filed with AMFI; none of it is a recommendation to buy, hold or sell. Past returns do not predict future ones. Generated 27 Sep 2026.